Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 73.6 44.7 164.6% View Chart
P/BV x 20.7 12.8 161.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ABBOTT INDIA
Mar-18
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2786,110 20.9%   
Low Rs8833,996 22.1%   
Sales per share (Unadj.) Rs228.41,552.2 14.7%  
Earnings per share (Unadj.) Rs10.4188.8 5.5%  
Cash flow per share (Unadj.) Rs16.3196.4 8.3%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.8796.6 12.4%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.3 145.3%   
Avg P/E ratio x104.226.8 389.5%  
P/CF ratio (eoy) x66.425.7 258.3%  
Price / Book Value ratio x10.96.3 172.4%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m27,008107,376 25.2%   
No. of employees `0001.43.3 40.8%   
Total wages/salary Rs m1,5353,937 39.0%   
Avg. sales/employee Rs Th4,210.99,929.3 42.4%   
Avg. wages/employee Rs Th1,132.21,185.1 95.5%   
Avg. net profit/employee Rs Th191.11,207.7 15.8%   
INCOME DATA
Net Sales Rs m5,71032,985 17.3%  
Other income Rs m1231,170 10.5%   
Total revenues Rs m5,83334,155 17.1%   
Gross profit Rs m4635,245 8.8%  
Depreciation Rs m147162 91.0%   
Interest Rs m038 0.0%   
Profit before tax Rs m4386,215 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,203 8.1%   
Profit after tax Rs m2594,012 6.5%  
Gross profit margin %8.115.9 51.0%  
Effective tax rate %40.835.4 115.2%   
Net profit margin %4.512.2 37.3%  
BALANCE SHEET DATA
Current assets Rs m3,20922,655 14.2%   
Current liabilities Rs m2,0706,681 31.0%   
Net working cap to sales %20.048.4 41.2%  
Current ratio x1.63.4 45.7%  
Inventory Days Days7265 111.7%  
Debtors Days Days3529 119.8%  
Net fixed assets Rs m790835 94.6%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m2,41916,715 14.5%   
Net worth Rs m2,46916,928 14.6%   
Long term debt Rs m00-   
Total assets Rs m4,60524,162 19.1%  
Interest coverage xNM163.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.4 90.8%   
Return on assets %5.616.8 33.6%  
Return on equity %10.523.7 44.3%  
Return on capital %17.736.9 48.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300369 81.3%   
Fx outflow Rs m2,0153,807 52.9%   
Net fx Rs m-1,715-3,438 49.9%   
CASH FLOW
From Operations Rs m881,527 5.8%  
From Investments Rs m-94-2,148 4.4%  
From Financial Activity Rs mNA-1,024 0.0%  
Net Cashflow Rs m-6-1,646 0.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS